These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 8047374)
1. Supplemental complement component C9 enhances the capacity of neonatal serum to kill multiple isolates of pathogenic Escherichia coli. Lassiter HA; Wilson JL; Feldhoff RC; Hoffpauir JM; Klueber KM Pediatr Res; 1994 Apr; 35(4 Pt 1):389-96. PubMed ID: 8047374 [TBL] [Abstract][Full Text] [Related]
2. Complement factor 9 deficiency in serum of human neonates. Lassiter HA; Watson SW; Seifring ML; Tanner JE J Infect Dis; 1992 Jul; 166(1):53-7. PubMed ID: 1607708 [TBL] [Abstract][Full Text] [Related]
3. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296 [TBL] [Abstract][Full Text] [Related]
4. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage. Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297 [TBL] [Abstract][Full Text] [Related]
5. Complement component C9 enhances the capacity of beta-lactam antibiotics to kill Escherichia coli in vitro and in vivo. Jung E; Feldhoff RC; Walz BM; Drehs MM; Buchheit JQ; Lassiter HA Am J Med Sci; 1998 May; 315(5):307-13. PubMed ID: 9587087 [TBL] [Abstract][Full Text] [Related]
6. The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsis. Lassiter HA; Walz BM; Wilson JL; Jung E; Calisi CR; Goldsmith LJ; Wilson RA; Morgan BP; Feldhoff RC Pediatr Res; 1997 Jul; 42(1):128-36. PubMed ID: 9212048 [TBL] [Abstract][Full Text] [Related]
7. Bactericidal activity of C9-deficient human serum. Pramoonjago P; Kinoshita T; Hong KS; Takata-Kozono Y; Kozono H; Inagi R; Inoue K J Immunol; 1992 Feb; 148(3):837-43. PubMed ID: 1730876 [TBL] [Abstract][Full Text] [Related]
8. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing. Tesh VL; Duncan RL; Morrison DC J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676 [TBL] [Abstract][Full Text] [Related]
9. The role of C9 in complement-mediated killing of Neisseria. Harriman GR; Esser AF; Podack ER; Wunderlich AC; Braude AI; Lint TF; Curd JG J Immunol; 1981 Dec; 127(6):2386-90. PubMed ID: 6795273 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies directed against gonococcal protein I vary in bactericidal activity. Joiner KA; Warren KA; Tam M; Frank MM J Immunol; 1985 May; 134(5):3411-9. PubMed ID: 3920319 [TBL] [Abstract][Full Text] [Related]
11. Multimeric C9 within C5b-9 is required for inner membrane damage to Escherichia coli J5 during complement killing. Bloch EF; Schmetz MA; Foulds J; Hammer CH; Frank MM; Joiner KA J Immunol; 1987 Feb; 138(3):842-8. PubMed ID: 3100618 [TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous immunoglobulin G on the deposition of immunoglobulin G and C3 onto type III group B streptococcus and Escherichia coli K1. Lassiter HA; Robinson TW; Brown MS; Hall DC; Hill HR; Christensen RD J Perinatol; 1996; 16(5):346-51. PubMed ID: 8915932 [TBL] [Abstract][Full Text] [Related]
13. Anti-capsular antibodies activate killing of Escherichia coli O8:K87 by the alternate complement pathway in porcine serum. Clark NM; Berberov EM; Wang M; Moxley RA Vet Immunol Immunopathol; 2006 Nov; 114(1-2):185-91. PubMed ID: 16919781 [TBL] [Abstract][Full Text] [Related]
14. Complement component 9 activation, consumption, and neuronal deposition in the post-hypoxic-ischemic central nervous system of human newborn infants. Schultz SJ; Aly H; Hasanen BM; Khashaba MT; Lear SC; Bendon RW; Gordon LE; Feldhoff PW; Lassiter HA Neurosci Lett; 2005 Apr; 378(1):1-6. PubMed ID: 15763162 [TBL] [Abstract][Full Text] [Related]
15. Further studies on C9 deficiency. Kitamura H; Nagaki K; Inai S J Clin Lab Immunol; 1981 Jul; 6(1):7-11. PubMed ID: 7265179 [TBL] [Abstract][Full Text] [Related]
16. The requirement of specific antibody for the killing of E. coli by the alternate complement pathway in bovine serum. Hill AW; Shears AL; Hibbitt KG Immunology; 1978 Jan; 34(1):131-6. PubMed ID: 75177 [TBL] [Abstract][Full Text] [Related]
17. An outer membrane-disorganizing peptide PMBN sensitizes E. coli strains to serum bactericidal action. Vaara M; Viljanen P; Vaara T; Mäkelä PH J Immunol; 1984 May; 132(5):2582-9. PubMed ID: 6325539 [TBL] [Abstract][Full Text] [Related]
18. Interaction of turkey complement with Escherichia coli isolated from turkeys. Ellis MG; Arp LH; Lamont SJ Am J Vet Res; 1989 Aug; 50(8):1285-9. PubMed ID: 2675694 [TBL] [Abstract][Full Text] [Related]
19. Polymerization of C9 enhances bacterial cell envelope damage and killing by membrane attack complex pores. Doorduijn DJ; Heesterbeek DAC; Ruyken M; de Haas CJC; Stapels DAC; Aerts PC; Rooijakkers SHM; Bardoel BW PLoS Pathog; 2021 Nov; 17(11):e1010051. PubMed ID: 34752492 [TBL] [Abstract][Full Text] [Related]
20. Sub-minimal inhibitory concentrations of cefmetazole enhance serum bactericidal activity in vitro by amplifying poly-C9 deposition. Schweinle JE; Nishiyasu M J Clin Invest; 1992 Apr; 89(4):1198-207. PubMed ID: 1556181 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]